Clinical Trial Results:
Safety study of IMOVAX Polio in selected cities in China, an observational post marketing study
Summary
|
|
EudraCT number |
2015-005185-34 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
10 Jul 2011
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Apr 2016
|
First version publication date |
16 Apr 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
IPV29
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01244464 | ||
WHO universal trial number (UTN) |
U1111-1114-3719 | ||
Sponsors
|
|||
Sponsor organisation name |
Sanofi Pasteur China
|
||
Sponsor organisation address |
6th Floor, No. 112 Jianguo Road, Chao Yang District, Beijing, China, 100022
|
||
Public contact |
Director, Clinical Development, Sanofi Pasteur China, 86 10 6568 5588 7386, jean-denis.shu@sanofipasteur.com
|
||
Scientific contact |
Director, Clinical Development, Sanofi Pasteur China, 86 10 6568 5588 7386, jean-denis.shu@sanofipasteur.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
07 May 2012
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
10 Jul 2011
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
- To describe the safety profile within 28 days after each dose of IMOVAX Polio administered at 2, 3 and 4 months of age in population aged over 2 months old living in the study city, China.
|
||
Protection of trial subjects |
Only subjects that met all the study inclusion and none of the exclusion criteria were randomized and vaccinated in the study. Vaccinations were performed by qualified and trained study personnel. Subjects with allergy to any of the vaccine components were not vaccinated. After vaccination, subjects were also kept under clinical observation for 30 minutes to ensure their safety. Appropriate medical equipment was also available on site in case of any immediate allergic reactions.
|
||
Background therapy |
Not applicable | ||
Evidence for comparator |
Not applicable | ||
Actual start date of recruitment |
15 Nov 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
China: 800
|
||
Worldwide total number of subjects |
800
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
800
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||
Recruitment
|
|||||||||||||||||
Recruitment details |
Study subjects were enrolled from 15 November 2010 to 7 March 2011 at 1 clinic center in China. | ||||||||||||||||
Pre-assignment
|
|||||||||||||||||
Screening details |
A total of 801 subjects were enrolled in the study; 800 subjects were vaccinated. | ||||||||||||||||
Period 1
|
|||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||
Blinding implementation details |
Not applicable
|
||||||||||||||||
Arms
|
|||||||||||||||||
Arm title
|
IMOVAX Polio™ | ||||||||||||||||
Arm description |
Infants at least 2 months of age received 3 doses of IMOVAX Polio™, 1 each at 2, 3, and 4 months of age. | ||||||||||||||||
Arm type |
Experimental | ||||||||||||||||
Investigational medicinal product name |
IMOVAX Polio™
|
||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||
Other name |
|||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular into the anterolateral area of the thigh or upper arm, 1 injection each at 2, 3, and 4 months of age.
|
||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
IMOVAX Polio™
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Infants at least 2 months of age received 3 doses of IMOVAX Polio™, 1 each at 2, 3, and 4 months of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
IMOVAX Polio™
|
||
Reporting group description |
Infants at least 2 months of age received 3 doses of IMOVAX Polio™, 1 each at 2, 3, and 4 months of age. |
|
|||||||||||||||||||||||||||||||
End point title |
Summary of Safety Endpoints After Any Vaccination Following A Three-Dose Primary Vaccination Series with Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) [1] | ||||||||||||||||||||||||||||||
End point description |
The following safety endpoints were assessed using The China State Food and Drug Administration (SFDA) severity scale: Solicited adverse reaction (Solicited systemic reaction and Solicited Injection site reaction), Unsolicited adverse event/adverse drug reaction (AE/ADR) (Unsolicited Injection site reaction, Unsolicited systemic AE, Unsolicited systemic ADR), Immediate event (Immediate ADR), Serious adverse events, and AEs leading to early termination of the study. The rate is the percentage of subjects with at least 1 event reported after any vaccine dose of administration. The immediate event was defined as the event that presented in the 30 minutes following vaccination. Solicited reactions (Fever, Injection site Erythema, Injection site Swelling) were assessed by both the Sponsor and the SFDA severity scales.
|
||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||
End point timeframe |
Day 0 up to Day 28 days post-any vaccination
|
||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive analyses were performed based on the study group and the study vaccine administered for this outcome. |
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Time of Onset and Number of Subjects with Solicited Injection-site and Systemic Reactions Following Each Primary Series Vaccination with Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) [2] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Solicited injection site and systemic reactions were assessed using the The China State Food and Drug Administration (SFDA) severity scale. Solicited Injection site reactions: Tenderness, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Somnolence, Anorexia, and Irritability. Fever, Injection site Erythema, Injection site Swelling were assessed by both the Sponsor and the SFDA severity scales.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 up to Day 3 post-each and any vaccination, Day 4 up to Day 7 post-each and any vaccination, and Day 0 up to Day 7 post-each and any vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive analyses were performed based on the study group and the study vaccine administered for this outcome. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [3] - N=786 Post-dose 2; N=772 Post-dose 3 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects with Unsolicited Adverse Events Occurring Up to 28 Days After Any Primary Series Vaccination with Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) [4] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
For the reporting of unsolicited AEs, if a subject had more than one event for a particular SOC/Preferred Term he/she was counted only once for that SOC/Preferred Term according to the most severe category.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 up to Day 28 post-any vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive analyses were performed based on the study group and the study vaccine administered for this outcome. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse event data were collected from Day 0 up to Day 28 post-any vaccination.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
13.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
IMOVAX Polio™
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Infants at least 2 months of age received 3 doses of IMOVAX Polio™, 1 each at 2, 3, and 4 months of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |